Your browser is no longer supported. Please, upgrade your browser.
Settings
GHDX Genomic Health, Inc. daily Stock Chart
GHDX [NASD]
Genomic Health, Inc.
Index- P/E- EPS (ttm)-0.15 Insider Own1.90% Shs Outstand34.30M Perf Week0.33%
Market Cap1.03B Forward P/E87.27 EPS next Y0.34 Insider Trans-15.87% Shs Float33.68M Perf Month-9.77%
Income-5.00M PEG- EPS next Q0.00 Inst Own91.20% Short Float2.68% Perf Quarter0.33%
Sales334.50M P/S3.08 EPS this Y59.30% Inst Trans1.57% Short Ratio8.08 Perf Half Y5.33%
Book/sh4.94 P/B6.08 EPS next Y5633.33% ROA-2.50% Target Price32.20 Perf Year10.94%
Cash/sh3.20 P/C9.38 EPS next 5Y5.50% ROE-3.20% 52W Range25.66 - 33.97 Perf YTD2.14%
Dividend- P/FCF411.87 EPS past 5Y-29.50% ROI-10.80% 52W High-13.01% Beta0.79
Dividend %- Quick Ratio4.00 Sales past 5Y9.70% Gross Margin83.90% 52W Low15.16% ATR0.83
Employees846 Current Ratio4.00 Sales Q/Q4.30% Oper. Margin-2.20% RSI (14)31.98 Volatility1.89% 2.77%
OptionableYes Debt/Eq0.00 EPS Q/Q56.80% Profit Margin-1.50% Rel Volume0.71 Prev Close30.02
ShortableYes LT Debt/Eq0.00 EarningsAug 01 AMC Payout- Avg Volume111.96K Price29.55
Recom2.70 SMA20-5.36% SMA50-7.91% SMA200-4.33% Volume78,018 Change-1.57%
May-03-17Downgrade Raymond James Outperform → Mkt Perform
Jan-18-17Initiated Deutsche Bank Hold $31
Feb-11-16Reiterated Canaccord Genuity Buy $44 → $38
Jan-11-16Downgrade Piper Jaffray Overweight → Neutral
Jan-07-16Reiterated Barclays Underweight $25 → $27
Jan-06-16Upgrade Canaccord Genuity Hold → Buy $26 → $44
Nov-23-15Upgrade UBS Neutral → Buy $29 → $38
Nov-04-15Upgrade Raymond James Mkt Perform → Outperform
Sep-02-15Initiated Barclays Underweight $25
Aug-28-15Upgrade Raymond James Underperform → Mkt Perform
Aug-05-15Reiterated Canaccord Genuity Hold $28 → $26
Mar-10-15Initiated UBS Neutral $34
Aug-11-14Reiterated Canaccord Genuity Hold $30 → $27
Aug-02-13Reiterated MLV & Co Hold $30 → $35
Feb-21-12Downgrade GARP Research Buy → Neutral
Feb-08-12Downgrade MLV & Co Buy → Hold $31.50 → $30
Dec-12-11Reiterated Ladenburg Thalmann Buy $26 → $32
Nov-02-11Upgrade Ladenburg Thalmann Neutral → Buy $26
Oct-11-11Reiterated RBC Capital Mkts Sector Perform $27 → $21
Oct-05-11Initiated Oppenheimer Perform $20
Aug-13-17 09:10AM  Edited Transcript of GHDX earnings conference call or presentation 1-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-11-17 08:02PM  Genomic Health, Inc. Value Analysis (NASDAQ:GHDX) : August 12, 2017 Capital Cube
Aug-03-17 10:00AM  Genomic Health, Inc.: Still Waiting for Reimbursement Motley Fool
Aug-02-17 11:08AM  Genomic Health (GHDX) Posts Wider-than-Expected Loss in Q2 Zacks -5.46%
08:06AM  Can DENTSPLY Sirona (XRAY) Deliver a Beat in Q2 Earnings? Zacks
Aug-01-17 10:12PM  Genomic Health reports 2Q loss Associated Press
04:05PM  Genomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress PR Newswire
11:00AM  Investor Network: Genomic Health, Inc. to Host Earnings Call ACCESSWIRE
Jul-28-17 09:36AM  Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : July 28, 2017 Capital Cube
Jul-20-17 08:00AM  Genomic Health to Announce Second Quarter 2017 Financial Results and Host Conference Call on Tuesday, August 1, 2017 PR Newswire
Jul-12-17 08:00AM  Updated St. Gallen International Breast Cancer Guidelines Reinforce Important Role of Genomic Testing in Treatment of Early Breast Cancer PR Newswire
Jun-29-17 03:02PM  ETFs with exposure to Genomic Health, Inc. : June 29, 2017 Capital Cube
Jun-21-17 08:29AM  Genomic Health Cancer Tests Strong, Operating Expenses a Woe Zacks
Jun-14-17 09:47AM  Genomic Health, Inc. :GHDX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube
Jun-13-17 03:41AM  Why Is Genomic Health (GHDX) Up 7.1% Since the Last Earnings Report? Zacks
Jun-02-17 08:00AM  Genomic Health Presents Data Further Demonstrating Ability of Oncotype DX® Tests to Optimize Outcomes in Patients Across Cancer Types PR Newswire
Jun-01-17 12:06PM  Genomic Health to Unveil Oncotype DX Study Results at ASCO Zacks
May-31-17 08:45AM  Genomic Health (GHDX) Looks Good: Stock Adds 5.2% in Session Zacks
May-30-17 03:02PM  3 Things Investors Should Know About Genomic Health Stock Motley Fool +5.23%
08:00AM  Genomic Health Announces Presentation of Eight Oncotype DX® Studies at the 2017 American Society of Clinical Oncology Annual Meeting Reinforcing Unique Impact Across Cancer Types PR Newswire
May-25-17 08:00AM  Genomic Health to Present at Jefferies 2017 Healthcare Conference PR Newswire
May-17-17 09:01AM  Genomic Health Q1 Results Weak, Cancer Test Business Strong Zacks
May-16-17 09:41AM  Genomic Health's (GHDX) Oncotype DX GPS Test Data Positive Zacks
May-15-17 05:00PM  Genomic Health, Inc. Waits for Reimbursement Motley Fool
May-14-17 11:16PM  Edited Transcript of GHDX earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-13-17 07:00AM  Prospective Oncotype DX® Genomic Prostate Score Test Data Presented at AUA and Published in Urology Establish Test's Ability to Increase Use and Persistence on Active Surveillance in Prostate Cancer Patients PR Newswire
May-12-17 05:05PM  Genomic Health, Inc. Value Analysis (NASDAQ:GHDX) : May 12, 2017 Capital Cube
12:48PM  Oncotype DX® Genomic Prostate Score (GPS) Test Predicts 10-year Risk of Prostate Cancer-specific Death and Metastases in Patients with Early-stage Disease PR Newswire
May-11-17 10:15AM  Genomic Health (GHDX) Misses Q1 Earnings & Sales Estimates Zacks
08:58AM  Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : May 11, 2017 Capital Cube
May-10-17 08:15PM  Edited Transcript of GHDX earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents -8.68%
08:00AM  Genomic Health to Present at Bank of America Merrill Lynch 2017 Health Care Conference PR Newswire
May-09-17 05:40PM  Genomic Health reports 1Q loss Associated Press
04:05PM  Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress PR Newswire
10:15AM  Investor Network: Genomic Health, Inc. to Host Earnings Call Accesswire
May-08-17 08:15AM  Blog Coverage: Genomic Health Announces Favorable LCD on Medicare Coverage for Use of Oncotype DX Genomic Prostate Score Accesswire
May-04-17 04:05PM  Genomic Health Announces Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of Oncotype DX® Genomic Prostate Score in Patients with Favorable Intermediate-risk Prostate Cancer PR Newswire
08:00AM  Genomic Health Announces Upcoming Presentation of Four Oncotype DX® Studies Including New Validation on Its Ability to Predict Prostate Cancer-specific Death and Metastases PR Newswire
May-02-17 08:00AM  Genomic Health to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017 PR Newswire
Apr-26-17 09:30AM  Zacks.com featured highlights: Cabot Oil & Gas, Cardiovascular Systems, Fortress Transportation and Infrastructure, Genomic Health and Par Pacific Holdings Zacks
Mar-30-17 09:47AM  Genomic Health's GPS Predicts Metastatic Prostate Cancer Zacks
09:47AM  Genomic Health's GPS Predicts Metastatic Prostate Cancer at Investopedia
06:45AM  New Research Shows Oncotype DX® Breast Cancer Test Helps Reduce Burden of Chemotherapy CNW Group
Mar-29-17 08:00AM  Oncotype DX® Predicts 10-year Risk of Developing Metastatic Prostate Cancer in Low- and Intermediate-risk Patients PR Newswire
Mar-24-17 08:00AM  Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results PR Newswire
Mar-22-17 09:11AM  Genomic Health's Cancer Test Business Strong, Expenses High Zacks
07:20AM  Genomic Health (GHDX) Up 2.1% Since Earnings Report: Can It Continue? Zacks
Mar-21-17 01:04PM  GENOMIC HEALTH INC Financials
08:34AM  Genomic Health's Breast Recurrence Test Data Encouraging Zacks
Mar-20-17 08:00AM  Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy PR Newswire
Mar-15-17 04:30PM  GENOMIC HEALTH INC Files SEC form 10-K, Annual Report
Mar-07-17 01:23PM  The Best Bet in the Growing Genetic Testing Market: Genetic Health vs. Invitae Motley Fool
01:23PM  The Best Bet in the Growing Genetic Testing Market: Genetic Health vs. Invitae at Motley Fool
Feb-28-17 08:00AM  Genomic Health to Present at the Cowen and Company 37th Annual Health Care Conference PR Newswire
Feb-24-17 09:24AM  3 Most Wildly Overvalued Stocks in Healthcare at Motley Fool
Feb-22-17 02:17PM  Genomic Health, Inc. :GHDX-US: Earnings Analysis: 2016 By the Numbers : February 22, 2017
Feb-21-17 07:11AM  Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : February 21, 2017
Feb-16-17 11:05AM  Genomic Health, Inc. :GHDX-US: Earnings Analysis: Q4, 2016 By the Numbers : February 16, 2017 -8.42%
08:00AM  Four New Studies of Oncotype DX® Genomic Prostate Score (GPS) Reconfirm Value of Test in Guiding Early-stage Prostate Cancer Risk Assessment and Treatment Selection PR Newswire
Feb-15-17 07:34PM  Why Genomic Health Inc. Jumped Higher Today at Motley Fool +10.24%
04:17PM  Genomic Health, Inc. Swings to a Profit at Motley Fool
08:57AM  Genomic Health (GHDX) Earnings Surpass Estimates in Q4
Feb-14-17 09:26PM  Edited Transcript of GHDX earnings conference call or presentation 14-Feb-17 9:30pm GMT
05:05PM  Genomic Health tops 4Q profit forecasts
04:19PM  GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
04:05PM  Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook PR Newswire
07:07AM  Q4 2016 Genomic Health Inc Earnings Release - After Market Close
Feb-07-17 08:00AM  Genomic Health to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 14, 2017 PR Newswire
Jan-18-17 03:57PM  Coverage initiated on Genomic Health by Deutsche Bank
12:29PM  Deutsche Bank Optimistic On Fundamentals In Life Science Tools/Diagnostics Sector
Jan-14-17 12:10PM  Why Exact Sciences' Stock Could Go Much Higher at Motley Fool
Jan-03-17 08:00AM  Genomic Health to Present at the 35th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-22-16 08:00AM  Genomic Health Announces Inclusion of Oncotype DX® in the 8th Edition of American Joint Committee on Cancer (AJCC) Criteria for Breast Cancer Staging PR Newswire
Dec-20-16 07:38AM  Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : December 20, 2016
Dec-15-16 04:25PM  GENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers
Dec-14-16 11:29PM  Is Genomic Health, Inc. (GHDX) A Good Stock To Buy? at Insider Monkey
Dec-12-16 09:59AM  Genomic Health Posts Impressive Data for Oncotype DX Test
07:24AM  Will Endopredict Win Myriad's (MYGN) Genomic Testing War?
Dec-09-16 08:40AM  Genomic Health Announces Results from Multiple Oncotype DX® Studies, Reinforcing its Impact in Delivering Precision Medicine to Breast Cancer Patients Around the World PR Newswire
Dec-07-16 08:16AM  Genomic Health: Cancer Test Business Strong, Q3 Dismal
Dec-05-16 02:03PM  Genomic Health, Inc. Value Analysis (NASDAQ:GHDX) : December 5, 2016
Dec-02-16 11:20AM  Hedge Funds Begin to Sour on Kulicke and Soffa Industries Inc. (KLIC) at Insider Monkey
07:44AM  Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : December 2, 2016
Nov-29-16 08:00AM  Genomic Health Announces Presentation of Multiple Oncotype DX® Studies at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium, Reinforcing Value of Genomics in Precision Medicine PR Newswire
Nov-04-16 04:19PM  GENOMIC HEALTH INC Files SEC form 10-Q, Quarterly Report
Nov-03-16 10:23PM  Genomic Health, Inc.: Almost at Breakeven at Motley Fool
08:31AM  Genomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : November 3, 2016
08:00AM  Genomic Health to Present at the Credit Suisse 25th Annual Healthcare Conference PR Newswire
Nov-02-16 09:26AM  Genomic Health (GHDX) Posts Wider-than-Expected Q3 Loss
Nov-01-16 07:42PM  Edited Transcript of GHDX earnings conference call or presentation 1-Nov-16 8:30pm GMT
06:02PM  Genomic Health reports 3Q loss
04:25PM  GENOMIC HEALTH INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Results of Operations and Fina
04:05PM  Genomic Health Reports Third Consecutive Quarter of Double-Digit Revenue Growth in Announcement of Third Quarter 2016 Financial Results PR Newswire
04:04PM  Genomic Health Announces Positive Topline Clinical Validation Study Results Demonstrating Oncotype DX® Prostate Cancer Test Predicts Risk of Metastasis and Mortality PR Newswire
07:07AM  Q3 2016 Genomic Health Inc Earnings Release - After Market Close
Oct-26-16 09:15AM  Comprehensive Economic Analysis Published in Reviews in Urology Demonstrates Oncotype DX® Prostate Cancer Test Leads to Substantial Cost Savings and Increase in Active Surveillance PR Newswire
Oct-25-16 08:00AM  Genomic Health to Announce Third Quarter 2016 Financial Results and Host Conference Call on Tuesday, November 1, 2016 PR Newswire
Oct-13-16 01:00AM  This Innovative Healthcare Stock Belongs In My Portfolio -- What About Yours?
Oct-11-16 08:00AM  Genomic Health Presents Robust Analytical Validation Study Results of Oncotype SEQ Liquid Biopsy Mutation Panel PR Newswire
Oct-10-16 08:00AM  Multiple Oncotype DX® Presentations at ESMO 2016 Congress Reinforce Its Unique Clinical Utility with Prospective Outcomes Results in Over 63,000 Breast Cancer Patients PR Newswire
Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype SEQ Liquid Select test, a non-invasive liquid biopsy test, which uses next-generation sequencing to identify and select actionable genomic alterations to quantify the presence and burden of cancer, as well as helps to predict the sensitivity or resistance to specific drugs for patients with certain late-stage cancers, such as lung, breast, colon, melanoma, ovarian, or gastrointestinal cancers. Its development stage pipeline products include Oncotype TRACK products for non-invasive tumor monitoring. The company offers its products through a network of distributors. Genomic Health, Inc. has a collaboration agreement with Epic Sciences, Inc. The company was founded in 2000 and is based in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Popovits Kimberly JPresident and CEOAug 14Option Exercise17.335,00086,65084,057Aug 16 08:02 PM
Popovits Kimberly JPresident and CEOAug 14Sale30.225,000151,11179,057Aug 16 08:02 PM
Cole G BradleyCOOAug 08Option Exercise17.335,00086,65044,935Aug 09 07:51 PM
Vaughn James JChief Commercial OfficerAug 08Option Exercise23.316,500151,51537,785Aug 09 07:52 PM
Vaughn James JChief Commercial OfficerAug 08Sale30.598,000244,72429,785Aug 09 07:52 PM
Cole G BradleyCOOAug 08Sale30.575,000152,84639,935Aug 09 07:51 PM
Febbo Phillip G.Chief Medical OfficerJul 19Sale33.573,174106,53817,800Jul 21 04:20 PM
Cole G BradleyCOOJul 11Option Exercise17.335,00086,65044,935Jul 13 05:23 PM
Cole G BradleyCOOJul 11Sale32.535,000162,66739,935Jul 13 05:23 PM
Popovits Kimberly JPresident and CEOJul 05Option Exercise17.331,46825,44080,525Jul 06 07:28 PM
Popovits Kimberly JPresident and CEOJul 05Sale32.671,46847,95279,057Jul 06 07:28 PM
Popovits Kimberly JPresident and CEOJul 03Option Exercise17.333,53261,21082,589Jul 06 07:28 PM
Popovits Kimberly JPresident and CEOJul 03Sale32.563,532114,98879,057Jul 06 07:28 PM
Shak StevenChief Scientific OfficerJun 23Option Exercise23.315,000116,550336,924Jun 27 06:11 PM
Shak StevenChief Scientific OfficerJun 23Sale33.275,000166,371331,924Jun 27 06:11 PM
Cole G BradleyCOOJun 13Option Exercise17.335,00086,65044,935Jun 15 04:40 PM
Cole G BradleyCOOJun 13Sale31.675,000158,34239,935Jun 15 04:40 PM
Popovits Kimberly JPresident and CEOJun 05Option Exercise17.335,00086,65084,057Jun 07 07:07 PM
Popovits Kimberly JPresident and CEOJun 05Sale32.325,000161,58279,057Jun 07 07:07 PM
BAKER BROS. ADVISORS LPDirectorMay 31Option Exercise18.1349,500897,43511,359,212Jun 01 05:19 PM
Shak StevenChief Scientific OfficerMay 23Option Exercise23.315,000116,550336,103May 25 04:39 PM
Shak StevenChief Scientific OfficerMay 23Sale29.405,000146,981331,103May 25 04:39 PM
Cohen Fred EDirectorMay 19Option Exercise14.378,250118,55374,145May 23 08:16 PM
Cohen Fred EDirectorMay 19Sale29.548,250243,74565,895May 23 08:16 PM
Cohen Fred EDirectorMay 18Option Exercise18.0516,500297,74382,395May 22 06:59 PM
Cohen Fred EDirectorMay 18Sale29.8816,500493,04065,895May 22 06:59 PM
Cohen Fred EDirectorMay 16Option Exercise18.138,250149,57374,145May 18 07:52 PM
Cohen Fred EDirectorMay 16Sale30.688,250253,10265,895May 18 07:52 PM
Popovits Kimberly JPresident and CEOMay 03Option Exercise17.335,00086,65083,236May 04 05:12 PM
Popovits Kimberly JPresident and CEOMay 03Sale31.775,000158,84978,236May 04 05:12 PM
Shak StevenChief Scientific OfficerApr 24Option Exercise23.315,000116,550336,103Apr 26 05:09 PM
Shak StevenChief Scientific OfficerApr 24Sale31.465,000157,323331,103Apr 26 05:09 PM
Popovits Kimberly JPresident and CEOApr 03Option Exercise20.805,000103,99283,236Apr 05 05:25 PM
Popovits Kimberly JPresident and CEOApr 03Sale31.305,000156,50778,236Apr 05 05:25 PM
Shak StevenChief Scientific OfficerMar 23Option Exercise23.315,000116,550336,103Mar 24 07:05 PM
Shak StevenChief Scientific OfficerMar 23Sale31.265,000156,295331,103Mar 24 07:05 PM
Leber LauraChief Communication OfficerMar 20Sale31.883,07297,94114,627Mar 22 04:03 PM
Cole G BradleyCOOMar 08Option Exercise23.315,610130,76945,338Mar 10 06:21 PM
Cole G BradleyCOOMar 08Sale31.555,710180,13439,528Mar 10 06:21 PM
Popovits Kimberly JPresident and CEOMar 06Option Exercise23.312906,76078,526Mar 07 08:34 PM
Popovits Kimberly JPresident and CEOMar 06Sale31.082909,01478,236Mar 07 08:34 PM
Popovits Kimberly JPresident and CEOMar 03Option Exercise23.314,710109,79082,946Mar 07 08:34 PM
Popovits Kimberly JPresident and CEOMar 03Sale31.094,710146,44078,236Mar 07 08:34 PM
Shak StevenChief Scientific OfficerFeb 23Option Exercise23.315,000116,550336,103Feb 27 09:56 PM
Shak StevenChief Scientific OfficerFeb 23Sale29.365,000146,815331,103Feb 27 09:56 PM
Febbo Phillip G.Chief Medical OfficerFeb 16Sale30.092,49575,06420,644Feb 17 06:44 PM
Cole G BradleyCOOFeb 15Option Exercise23.315,000116,55048,022Feb 17 06:43 PM
Cole G BradleyCOOFeb 15Sale29.005,000145,00043,022Feb 17 06:43 PM
Shak StevenChief Scientific OfficerJan 23Option Exercise23.315,000116,550332,207Jan 25 08:01 PM
Shak StevenChief Scientific OfficerJan 23Sale27.285,000136,387327,207Jan 25 08:01 PM
Cole G BradleyCOOJan 10Option Exercise23.315,000116,55040,882Jan 12 05:39 PM
Cole G BradleyCOOJan 10Sale29.225,000146,08735,882Jan 12 05:39 PM
Cole G BradleyCOODec 06Option Exercise23.315,000116,55040,882Dec 08 08:12 PM
Cole G BradleyCOODec 06Sale30.615,000153,03035,882Dec 08 08:12 PM
Popovits Kimberly JPresident and CEODec 05Option Exercise23.315,000116,55064,620Dec 06 07:17 PM
Popovits Kimberly JPresident and CEODec 05Sale30.025,000150,10059,620Dec 06 07:17 PM
Leber LauraChief Communication OfficerNov 21Option Exercise17.413,60062,67621,399Nov 23 02:43 PM
Leber LauraChief Communication OfficerNov 21Sale31.737,068224,26614,331Nov 23 02:43 PM
Shak StevenChief Scientific OfficerNov 10Option Exercise18.895,00094,450330,534Nov 15 04:56 PM
Shak StevenChief Scientific OfficerNov 10Sale31.715,000158,569327,207Nov 15 04:56 PM
Cole G BradleyCOONov 08Option Exercise23.315,000116,55040,426Nov 10 07:37 PM
Cole G BradleyCOONov 08Sale29.685,000148,42235,426Nov 10 07:37 PM
Popovits Kimberly JPresident and CEONov 03Option Exercise18.895,313100,36364,933Nov 07 06:53 PM
Popovits Kimberly JPresident and CEONov 03Sale28.885,313153,42359,620Nov 07 06:53 PM
Shak StevenChief Scientific OfficerOct 11Option Exercise18.895,00094,450332,207Oct 12 07:24 PM
Shak StevenChief Scientific OfficerOct 11Sale30.395,000151,925327,207Oct 12 07:24 PM
Cole G BradleyCOOOct 10Option Exercise21.188,290175,56039,716Oct 12 06:07 PM
Cole G BradleyCOOOct 10Sale30.598,290253,57235,426Oct 12 06:07 PM
Vaughn James JChief Commercial OfficerOct 06Sale29.683,00089,04226,079Oct 11 08:07 PM
Shak StevenChief Scientific OfficerSep 13Option Exercise18.895,00094,450332,207Sep 15 06:25 PM
Shak StevenChief Scientific OfficerSep 13Sale26.835,000134,156327,207Sep 15 06:25 PM
Cole G BradleyCOOSep 06Option Exercise18.894,00075,56039,426Sep 08 06:36 PM
Cole G BradleyCOOSep 06Sale27.414,000109,63735,426Sep 08 06:36 PM
Shak StevenChief Scientific OfficerAug 23Option Exercise18.895,00094,450332,207Aug 25 06:49 PM
Shak StevenChief Scientific OfficerAug 23Sale27.245,000136,215327,207Aug 25 06:49 PM